A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.
about
Evidence for placebo effects on physical but not on biochemical outcome parameters: a review of clinical trialsVitamin D and the vitamin D receptor are critical for control of the innate immune response to colonic injuryMaintenance Infliximab Treatment Is Associated with Improved Bone Mineral Density in Crohn's DiseaseDefects in mucosal immunity leading to Crohn's diseaseBudesonide for induction of remission in Crohn's diseaseAnti-IL-12/23p40 antibodies for induction of remission in Crohn's diseaseSargramostim (GM-CSF) for induction of remission in Crohn's diseaseThalidomide and thalidomide analogues for induction of remission in Crohn's diseaseTumor necrosis factor-alpha antibody for maintenance of remission in Crohn's diseaseBudesonide for induction of remission in Crohn's diseaseTumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitisTumor necrosis factor-alpha antibody for induction of remission in Crohn's diseaseInflammatory bowel disease reveals the kinase activity of KSR1Virus-plus-susceptibility gene interaction determines Crohn's disease gene Atg16L1 phenotypes in intestineVedolizumab for the treatment of ulcerative colitis and Crohn's diseaseTumour necrosis factor alpha converting enzyme (TACE) activity in the colonic mucosa of patients with inflammatory bowel diseaseIL-23 receptor (IL-23R) gene protects against pediatric Crohn's diseasePhysiology and immunology of the cholinergic antiinflammatory pathwayBehçet's diseaseInflammatory bowel disease surgery in the biologic eraThe role of vedolizumab in patients with moderate-to-severe Crohn's disease and ulcerative colitisSelective biologics for ulcerative colitis and Crohn's disease - clinical utility of vedolizumabMacrophage migration inhibitory factor: a potential therapeutic target for rheumatoid arthritisUstekinumab for the treatment of Crohn's disease: can it find its niche?The Role of Neuropeptides in Mouse Models of ColitisNanomedicine and drug delivery strategies for treatment of inflammatory bowel diseaseHow should immunomodulators be optimized when used as combination therapy with anti-tumor necrosis factor agents in the management of inflammatory bowel disease?Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological TreatmentsInterventions and targets aimed at improving quality in inflammatory bowel disease ambulatory careProfile of ustekinumab and its potential in patients with moderate-to-severe Crohn's disease.Evidence-based clinical practice guidelines for Crohn's disease, integrated with formal consensus of experts in JapanClassical and recent advances in the treatment of inflammatory bowel diseasesA review of the impact of biologics on surgical complications in Crohn's diseaseOptimization of the treatment with immunosuppressants and biologics in inflammatory bowel diseaseClinical use and mechanisms of infliximab treatment on inflammatory bowel disease: a recent updateInflammatory pathways of importance for management of inflammatory bowel diseaseRedeeming an old foe: protective as well as pathophysiological roles for tumor necrosis factor in inflammatory bowel diseaseUse of the tumor necrosis factor-blockers for Crohn's diseaseMolecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseasesTHERAPIES FOR CROHN'S DISEASE: a clinical update
P2860
Q21245273-BBF99109-7F2D-445F-9AB0-6E446CD7EEC5Q21263129-C5D921E5-C859-40F1-8183-B410F785130BQ22242347-3F6EAEE9-515B-4815-A7B7-CE45E91DC4EFQ22242645-E80E7DC6-D722-42E2-BBB2-634DC36E5AAEQ24187309-FFE3635E-6FEC-4F2A-9CD9-B451C6176B3AQ24188040-5A6F6FBF-7531-4D77-927F-FB57AD30EF27Q24235068-83D7BA0D-1418-4F7C-A10D-CFEE5011B9FBQ24241766-CE6C60CA-502F-40C2-8A85-B4A415E148F0Q24242101-F46CB99C-A2C7-4E3D-8229-D5ED50D2387CQ24242729-050A48A6-953E-4386-B99C-61242D7BF208Q24245033-E0925D5E-7660-4A26-97CD-D1603D08CDCDQ24247745-AB5ABB18-4D90-43CF-B521-0717BA68CA11Q24562733-A9899950-3572-4816-93EC-F2C8C6F1FD07Q24604466-23E192AA-FFF9-4DE0-9689-EFCCEE238BB2Q24630083-FBF1F2B4-AF39-4EDD-A5A8-45FC05FB6015Q24669999-447FCB0E-CDFD-4499-9305-C6513A887F28Q24681096-DA8F7C98-79D9-44AF-BE35-FA64936C79CDQ24681833-DFFF830B-9C69-4320-9336-F254522D9900Q24804631-683F14DB-D371-46E6-B1CE-88AB56D31D20Q26745627-1D643B49-4B36-4C94-8259-9C01B03BDB85Q26748626-9CA386C4-5778-4FCC-AC36-F1B071869B34Q26750456-6C1123C1-22D2-4B31-BA66-4705A2644E7CQ26750562-25592138-7DC6-47AF-AD32-3806D5176B44Q26771890-3D5242C9-BF30-4F44-AA87-8906440AC2E8Q26773507-590A9347-A883-4369-9DA1-AA2064C26001Q26777400-C57AB933-6E6E-46E3-8716-B654BCFB5E36Q26777409-9EB54760-AC39-4DAA-9CAE-1BEC909E777EQ26785537-98BAEA5D-AB67-41E2-9295-CEA73733FBE9Q26823569-6A1CA3E1-E2EB-48A8-85EE-CB8EBFC5627AQ26825174-9AA19895-ED69-449D-86B6-BEE896B68B51Q26829392-F80CE7BA-8BFF-49F0-AC23-F68ACE620FD9Q26861725-315EA0FD-D5E7-43A7-A1BC-C24911B07DBBQ26865009-DBD4B46B-FCC9-438A-9581-814415529955Q26866940-10ACF502-F909-488A-8D56-26876E40267EQ26994776-5EF57014-D735-4515-88DE-E14DBBB41D1DQ27005445-8FE75C0F-1F91-4C08-B057-5B3A05635044Q27027630-0D2F5CA1-FC4A-4184-8939-AF3A6CCD43F9Q27030762-3FD77876-533D-4D50-A060-834D51635652Q28067245-9F11D47A-3ECA-4D97-B496-48AF514609EEQ28070271-F3588E51-54BC-4BB9-A234-12EC63E8FA6F
P2860
A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh
1997年學術文章
@zh-hant
name
A short-term study of chimeric ...... ohn's Disease cA2 Study Group.
@en
A short-term study of chimeric ...... ohn's Disease cA2 Study Group.
@nl
type
label
A short-term study of chimeric ...... ohn's Disease cA2 Study Group.
@en
A short-term study of chimeric ...... ohn's Disease cA2 Study Group.
@nl
prefLabel
A short-term study of chimeric ...... ohn's Disease cA2 Study Group.
@en
A short-term study of chimeric ...... ohn's Disease cA2 Study Group.
@nl
P2093
P1476
A short-term study of chimeric ...... ohn's Disease cA2 Study Group.
@en
P2093
Braakman T
DeWoody KL
Hanauer SB
Present DH
Rutgeerts PJ
Schaible TF
van Deventer SJ
P304
P356
10.1056/NEJM199710093371502
P407
P577
1997-10-01T00:00:00Z